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Abstract: Enrofloxacin (ENRO) is a poorly soluble drug used in veterinary medicine. It differs from
the more widely used fluoroquinolone ciprofloxacin (CIP) by the presence of an ethyl substituent on
its piperazine amino group. While a number of recent studies have examined amorphous composite
formulations of CIP, little research has been conducted with ENRO in this area. Therefore, the main
purpose of this work was to produce amorphous solid dispersions (ASDs) of ENRO. The solid-state
properties of these samples were investigated and compared to those of the equivalent CIP ASDs, and
their water uptake behavior, solubility, dissolution, and antibacterial activity were assessed. Like CIP,
X-ray amorphous solid dispersions were obtained when ENRO was ball milled with acidic polymers,
whereas the use of neutral polymers resulted in semi-crystalline products. Proton transfer from the
carboxylic acids of the polymers to the tertiary amine of ENRO’s piperazine group appears to occur
in the ASDs, resulting in an ionic bond between the two components. Therefore, these ASDs can be
referred to as amorphous polymeric salts (APSs). The glass transition temperatures of the APSs were
significantly higher than that of ENRO, and they were also resistant to crystallization when exposed
to high humidity levels. Greater concentrations were achieved with the APSs than the pure drug
during solubility and dissolution studies, and this enhancement was sustained for the duration of the
experiments. In addition, the antimicrobial activity of ENRO was not affected by APS formation,
while the minimum inhibitory concentrations and minimum bactericidal concentrations obtained
with the APS containing hydroxypropyl methylcellulose acetate succinate grade MG (HPMCAS-MG)
were significantly lower than those of the pure drug. Therefore, APS formation is one method of
improving the pharmaceutical properties of this drug.
Keywords: enrofloxacin; ciprofloxacin; amorphous solid dispersion; amorphous polymeric salt;
polymer; ball milling; solubility; dissolution
1. Introduction
Enrofloxacin (ENRO), or 1-cyclopropyl-7-(4-ethylpiperazin-1-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-
3-carboxylic acid, is a fluoroquinolone antibiotic that is licensed for veterinary use. ENRO differs from
the more widely known fluoroquinolone ciprofloxacin (CIP) by the presence of an ethyl substituent
in the N3 position (Figure 1). Anhydrous CIP generally exists in the zwitterionic state, with a
protonated amino group and negatively charged carboxylate group. These oppositely charged groups
form head-to-tail ionic bonds with neighboring and adjacent molecules, resulting in a tetramer-like
structure [1]. ENRO, on the other hand, is unionized in the solid state and can therefore only form a
number of weak C–H•••O and C–H•••N hydrogen bonds [2].
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Figure 1. Chemical structure of (a) enrofloxacin and (b) ciprofloxacin. 
CIP and ENRO are both poorly water-soluble drugs, with an intrinsic solubility of 
approximately 0.1 mg/mL and 0.4 mg/mL, respectively [3]. Both drugs are least soluble at pH 7.4 and 
exist predominantly in the zwitterionic form in neutral solutions [4]. Despite the theoretically higher 
hydrophilicity of CIP due to the absence of an aliphatic group in the N3 position, the strong crystal 
lattice of this drug reduces its aqueous solubility below that of ENRO. In addition, the extra ethyl 
group of ENRO increases its lipophilicity and permeability, resulting in greater absorption in rat in 
situ permeability studies than CIP [3]. However, the permeability of ENRO still falls within the limits 
of poorly permeable [5]. 
One of the most commonly used techniques to improve the solubility of ionizable drugs is salt 
formation. A number of crystalline ENRO salts have been produced by Karanam et al. and all were 
found to be significantly more water-soluble than the pure drug [2]. The piperazine N3 nitrogen of 
ENRO is positively charged in the salts containing acidic counterions, such as succinic acid, fumaric 
acid, and maleic acid, and forms an ionic bond with the carboxylate groups of the acids. The 
carboxylic acid of the drug, on the other hand, remains unionized. By contrast, ENRO exists in the 
anionic state in the ammonium salt, with a negatively charged carboxylate group and neutral 
piperazine group [2]. The solubility of ENRO was also increased significantly via formulation as the 
saccharinate salt. Like the equivalent CIP salt, an ionic interaction between the negatively charged 
saccharin molecule and positively charged N3 amino group of ENRO was detected in this compound 
[6]. 
The solubility of a drug may also be increased by converting it to the amorphous form. This 
involves the disruption of the crystal lattice, producing a disordered, high-energy version of the drug 
[7]. This approach is usually avoided during commercial drug development due to the intrinsic 
instability of amorphous solids. However, suitable excipients can be used to stabilize the amorphous 
form and prevent its crystallization. This stabilization is usually brought about via interactions 
between the components, such as hydrogen or ionic bonds, and/or through steric hindrance, e.g., by 
polymers with long chains [8]. Recently, the formation of various amorphous solid dispersions 
(ASDs) and amorphous salts of CIP was investigated by our group. Due to the poor solubility and 
thermal degradation of the drug, these were mainly prepared by ball milling [1,9]. Promising results 
were obtained with a number of CIP ASDs containing various acidic polymers. They were found to 
increase the glass transition temperature (Tg) and solubility of CIP, while the permeability and 
antibacterial activity of the drug was either unchanged or moderately improved [9]. As an ionic 
interaction between the drug and polymer was identified in each as these ASDs, they may also be 
referred to as amorphous polymeric salts (APSs) [9]. The majority of ASDs described in the literature 
are stabilized by nonionic interactions between the components, such as hydrogen bonds, and do not 
involve proton transfer between the drug and polymer. The apparent solubility of APSs may be even 
further improved in comparison to unionized ASDs, due to the amalgamation of both approaches, 
i.e., drug ionization and amorphization. 
Amorphous salts of CIP containing succinic acid or amino acids as counterions have also been 
prepared. While these formulations were far more soluble than the CIP ASDs, they were less stable 
when exposed to high humidity and in most cases decreased the permeability of the drug [10,11]. 
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CIP and ENRO are both poorly water-soluble drugs, with an intrinsic solubility of approximately
0.1 mg/ L and 0.4 mg/mL, respectively [3]. Both drugs are least soluble at pH 7.4 and exist
predominantly in the zwitterionic form in neutral solutions [4]. Despite the theoretically higher
hydrophilicity of CIP due to the absence of an aliphatic group in the 3 position, the strong crystal
lattice of this drug reduces its aqueous solubility belo that of E R . In addition, the extra ethyl
group of E RO increases its lipophilicity and permeability, resulting in greater absorption in rat in situ
permeability studies than CIP [3]. However, the permeability of ENRO still falls within the limits of
poorly permeable [5].
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for ation. nu ber of crystalline E R salts have been produced by Karana et al. and all ere
found to be significantly ore ater-soluble than the pure drug [2]. The piperazine 3 nitrogen of
E R is positively charged in the salts containing acidic counterions, such as succinic acid, fu aric
acid, and maleic acid, and forms an ionic bond with the carboxylate groups of the acids. The carboxylic
acid of the drug, on the other hand, remains unionized. By contrast, ENRO exists in the anionic state
in the ammonium salt, with a negatively charged carboxylate group and neutral piperazine group [2].
The solubility of ENRO was also increased significantly via formulation as the saccharinate salt. Like
the equivalent CIP salt, an ionic interaction between the negatively charged saccharin molecule and
positively charged N3 amino group of ENRO was detected in this compound [6].
The solubility of a drug may also be increased by converting it to the amorphous form. This
involves the disruption of the crystal lattice, producing a disordered, high-energy version of the drug [7].
This approach is usually avoided during commercial drug development due to the intrinsic instability
of amorphous solids. However, suitable excipients can be used to stabilize the amorphous form and
prevent its crystallization. This stabilization is usually brought about via interactions between the
components, such as hydrogen or ionic bonds, and/or through steric hindrance, e.g., by polymers with
long chains [8]. Recently, the formation of various amorphous solid dispersions (ASDs) and amorphous
salts of CIP was investigated by our group. Due to the poor solubility and thermal degradation of the
drug, these were mainly prepared by ball milling [1,9]. Promising results were obtained with a number
of CIP ASDs containing various acidic poly ers. They were found to increase the glass transition
temperature (Tg) and solubility of CIP, while the permeability and antibacterial activity of the drug
was either unchanged or moderately improved [9]. As an ionic interaction between the drug and
polymer was identified in each as these ASDs, they may also be referred to as amorphous polymeric
salts (APSs) [9]. The majority of ASDs described in the literature are stabilized by nonionic interactions
between the co ponents, such as hydrogen bonds, and do not involve proton transfer between the
drug and polymer. The apparent solubility of APSs may be even further improved in comparison to
unionized ASDs, due to the amalgamation of both approaches, i.e., drug ionization and amorphization.
Amor hous salts of CIP containing succinic acid or amino acids as counterions have also been
prepared. While these for ulations were far more soluble than the CIP ASDs, they were less stable
when exposed to high humidity and in most cases decreased the permeability of the drug [10,11].
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Unlike many other poorly soluble drugs, there is very little in the literature regarding amorphous
solid dispersions of ENRO, and no mention of the pure amorphous form of the drug. However,
one study by Chun and Choi described the preparation of an enrofloxacin–Carbopol “complex” by
mixing a solution of ENRO in 1% acetic acid with that of Carbopol in water, filtering and washing the
precipitate, and then drying and milling the resultant powder [12]. The product was found to be X-ray
amorphous but lacked a clear Tg. The authors hypothesized that the positively charged tertiary amine
of the drug formed an ionic bond with the carboxylate anions of Carbopol. Consequently, when the
dissolution rate of the complex was found to be lower than that of the pure drug, this was attributed to
the strength of the drug–polymer interactions.
Due to the absence of research in this area, the main aim of this project was to prepare ASDs
of ENRO and to examine their solid-state and pharmaceutical properties. As previously mentioned,
the chemical structure of ENRO differs from that of CIP by the presence of an ethyl group on its N3
piperazine amino group. It was of interest to determine whether this has an impact on the interactions
that the drug can form with various polymers and whether the biopharmaceutical properties of
this veterinary drug can be improved. The solid-state characteristics and water uptake behavior
of the successfully prepared dispersions were also examined and compared to those of equivalent
CIP ASDs produced in an earlier study [9]. In addition, the solubility, dissolution, and antibacterial
activity of the ENRO dispersions were investigated in order to determine the effect of physicochemical
transformations on these biopharmaceutical properties of the drug.
2. Materials and Methods
2.1. Materials
Enrofloxacin (ENRO) was obtained from Glentham Life Sciences (Wiltshire, UK) and Ciprofloxacin
(CIP) was purchased from Carbosynth Limited (Berkshire, UK). Polyvinylpyrrolidone K17 (PVP:
Plasdone C-15) was sourced from ISP Technologies (New Jersey, USA), poly(vinyl alcohol) (PVA:
98% hydrolyzed, Mw 13000–23000) was obtained from Sigma-Aldrich (St. Louis, MO, USA), and
Carbopol 981 was purchased from BF Goodrich (OH, USA). Methacrylic acid methyl methacrylate
copolymer (Eudragit L100) and methacrylic acid ethyl acrylate copolymer (Eudragit L100-55) were
kindly donated by Evonik Röhm GmbH (Darmstadt, Germany), while hydroxypropyl methylcellulose
acetate succinate grades LG and MG (HPMCAS-LG and HPMCAS-MG) were provided by Shin-Etsu
Chemical Co., Ltd. (Tokyo, Japan).
Fasted state simulated intestinal fluid (FaSSIF) was produced by adding 2.24 g SIF® Powder
Original (biorelevant.com, Surrey, UK) to one liter of FaSSIF phosphate buffer, consisting of 19.5 mM
NaOH (Riedel-de Haën, Seelze, Germany), 25 mM NaH2PO4·H2O (Merck, Darmstadt, Germany)
and 106 mM NaCl (Sigma-Aldrich Ireland Ltd., Arklow, Ireland), adjusted to pH 6.5 with NaOH.
Triethylamine was obtained from Sigma-Aldrich Ireland Ltd., (Arklow, Ireland). Brain–heart infusion
(BHI) broth was obtained from bioMérieux (Marcy l’Étoile, France), while plates with Columbia agar
supplemented with sheep blood were sourced from Oxoïd (Dardilly, France). All other chemicals and
solvents were of analytical grade.
2.2. Methods
2.2.1. Sample Preparation
Solid dispersions were produced by dry ball milling ENRO and various polymers as described
previously [9]. Briefly, the process was carried out at room temperature (22–25 ◦C) with a Retsch
planetary ball mill PM 100 (Haan, Germany). The polymer concentration used was 40–60% (w/w),
and a total of 2 g of powder was loaded to 50 mL stainless steel grinding jars containing three 20 mm
stainless steel milling balls. Each mixture was milled for 1–6 h in total, in intervals of 15 min with
10 min breaks in between. Crystalline ENRO was quench cooled by heating the drug to the endset
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of melting (~235 ◦C) at 10 ◦C/min in a differential scanning calorimetry (DSC) machine, and then
immediately removing the sample to allow it to cool quickly at room temperature. Physical mixtures
(PMs) were prepared by mixing relevant concentrations of ENRO and the polymers in a pestle and
mortar for a few minutes.
2.2.2. Powder X-ray Diffraction (PXRD)
PXRD was performed at room temperature using a benchtop Rigaku MiniflexII X-ray diffractometer
(Tokyo, Japan) and a Haskris cooler (Illinois, USA) as described previously [1].
2.2.3. Solid-State Fourier Transform Infrared Spectroscopy (FTIR)
A Spectrum One FTIR spectrometer (PerkinElmer, Connecticut, USA) was utilized to obtain FTIR
data [1,9]. The following parameters of the analysis, accumulating 10 scans in total, were employed:
450–4000 cm−1 was spectral range, 4 cm−1 was resolution, while the scan speed was 0.2 cm/s. A sample
concentration of 1% (w/w) was obtained, diluting the powdered sample with KBr and making disks
suitable for FTIR by applying pressure of approximately 10 bar for 1 min.
Deconvolution of the FTIR spectra was conducted to facilitate their comparison. OriginPro 7.5
software was used to subtract the baseline and carry out Gaussian peak fitting on the spectra. In each
case, seven overlapping peaks were detected in the region under examination, whose combined area
and shape were similar to those of the original bands [1].
2.2.4. Differential Scanning Calorimetry (DSC)
DSC analysis on 5–10 mg samples was done using a Mettler Toledo DSC (Schwerzenbach,
Switzerland) under nitrogen purge and employing sealed 40 µL aluminum pans with three pin-holes
in the lid [9]. To expose the glass transition temperature (Tg) of the samples, the powders were first
subjected to a first heating cycle from 25 to 65 ◦C to remove the residual moisture, then the samples
were cooled to 25 ◦C and re-heated to 250 ◦C at a rate of 10 ◦C/min.
2.2.5. Modulated Temperature Differential Scanning Calorimetry (MTDSC)
The Tgs of the ASDs were detected by MTDSC using a Q200 DSC instrument and TA Instruments
DSC Refrigerated Cooling System (TA Instruments, New Castle, Delaware). Samples of 3–4 mg were
heated in aluminum pans with sealed aluminum lids. Nitrogen was used as the purge gas at a flow
rate of 20 mL/min. Samples were heated from 0 ◦C to 110–185 ◦C at 2 ◦C/min, with an amplitude of ±
0.318 ◦C and a modulation period of 60 s. Results were analyzed with the Universal Analysis 2000
software (TA Instruments). The midpoint of the transition was taken as the Tg. Sapphire was used to
calibrate the heat capacity, while indium was used for the calibration of enthalpy and temperature. All
measurements were carried out in triplicate.
2.2.6. Calculation of Theoretical Glass Transition (Tg) Values with Gordon–Taylor Equation









w1 and w2 are the weight fractions of the components, Tg1 and Tg2 are the glass transition temperatures
of ENRO and the polymer, and ρ1 and ρ2 are the true densities of the two constituents. The Tgs of
the polymers were sourced from the literature: HPMCAS-LG, 119 ◦C [15]; HPMCAS-MG, 120 ◦C [15];
Eudragit L100, 130 ◦C [16]; Eudragit L100-55, 96 ◦C [16]; and Carbopol, 105 ◦C [17]. Further, the average
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true density data were obtained from the published resources: ENRO, 1.385 g/cm3 [18]; HPMCAS-LG
and HPMCAS-MG, 1.29 g/cm3 [19]; Eudragit L100, 0.84 g/cm3 [20]; Eudragit L100-55, 0.83 g/cm3 [16];
and Carbopol, 1.4 g/cm3 [21].
2.2.7. High-Speed Differential Scanning Calorimetry (HSDSC)
HSDSC was performed on crystalline ENRO, under helium purge, with a PerkinElmer Diamond
DSC (Waltham, MA, USA) supported by a ULSP B.V. 130 cooling system (Ede, The Netherlands) as
described previously [1]. Around 3–5 mg samples were first encapsulated in aluminum pans (18 µL)
and heated from 25 to 300 ◦C at a rate of 300–500 ◦C/min.
2.2.8. Thermogravimetric Analysis (TGA)
TGA was done using a Mettler TG50 measuring module coupled to a Mettler Toledo MT5 balance
(Schwerzenbach, Switzerland) [1]. The heating rate employed was 10 ◦C/min and samples (8–10 mg)
were loaded into open aluminum pans.
2.2.9. Dynamic Vapor Sorption (DVS) and Mathematical Modeling Using Young–Nelson Equations
DVS studies were performed using an Advantage-1 automated gravimetric vapor sorption
analyzer (Surface Measurement Systems Ltd., London, UK) at 25.0 ± 0.1 ◦C, between 0 and 90% RH,
in steps of 10% RH, as described previously [9]. The complete sorption and desorption profile is
shown as an isotherm. PXRD analysis was performed on all samples following DVS to identify any
solid-state transformations.
In order to determine how water uptake occurs in the ASDs, the experimental sorption and
desorption data were fitted to equations using the Young–Nelson model, as described previously [22,23]:
Ms = A(β + θ) + B(θ)RH, (3)
Md = A(β + θ) + B(θ)RHmax. (4)
Ms and Md are the amount of water sorbed and desorbed, respectively, at each relative humidity
value. This is expressed as a fraction of the dry mass of the sample. A and B are constants which can









ρw is the density of water, Wm is the weight of the dry sample, and VolM and VolA are the volume
of adsorbed and absorbed water, respectively. In Equations (3) and (4), θ represents the fraction of
sample surface that is covered by at least one layer of water molecules, and β is the mass of absorbed
water at 100% RH. B(θ)RH is therefore the mass of absorbed water at a particular fraction of monolayer
coverage, θ, and RH level. A(β + θ) is equal to the total amount of adsorbed water, while Aθ is the
mass of water in an entire adsorbed monolayer, as a fraction of the dry mass of the material. Aβ is the
mass of water adsorbed in a multilayer. θ and β may be further defined as follows [23]:
θ =
RH
RH+ E(1−RH) , (7)
β = − ERH
E− (E− 1)RH +
E2
(E− 1) ln a
E− (E− 1)RH
E
a− (E+ 1) ln(1−RH). (8)
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E is an equilibrium constant between water in the monolayer and condensed water adsorbed
externally to the monolayer:
E = e
−[ q1−qLkBT ]. (9)
q1 is the heat of adsorption of water on the solid, qL is the heat of condensation of water, both in
Joules/mole, then T is the temperature in Kelvin and kB is Boltzmann’s constant (1.38 × 10−23 J/K).
The experimental data obtained from DVS studies of the ENRO ASDs, as well as equivalent CIP
ASDs that were previously prepared [9], were fitted to Equations (3) and (4) by iterative multiple linear
regression. The sum of the squares of the residuals between the experimental and calculated values
was used as fitting criteria. The multiple correlation coefficient (r) was calculated using Microsoft Excel
2007. Using the calculated values of A, B, θ, and β, the profiles of water adsorbed in monolayer (Aθ)
and multilayer (Aβ), and of absorbed water (Bθ) were determined [23].
2.2.10. Dynamic Solubility Study
A volume of 5 mL of FaSSIF was added to 40 mL glass vials and placed into jacketed beakers
connected to a Lauda M12 waterbath at 37 ◦C (Lauda-Königshofen, Germany). A quantity of pure
drug or ASD, in excess of the expected saturated solubility (25–200 mg, depending on the sample), was
added to the vials containing the aliquot of FaSSIF and stirred at 1000 rpm. At different time points,
over a 2 h period, samples were taken for the stirred suspensions and filtered with 0.45 µm PTFE
membrane filters (VWR, USA). The filtered solutions were then diluted appropriately with a 2.9 g/L
solution of phosphoric acid, previously adjusted to pH 2.3 with trimethylamine [2]. The concentration
of ENRO in each of the diluted samples was determined by UV spectrophotometry as described below.
The solid material left in the vials at the end of the studies was filtered and analyzed by PXRD.
2.2.11. Dissolution Study
Dissolution studies were carried out at 37 ◦C, using a paddle apparatus (Apparatus II) with a
continuous rotation of 100 rpm. A quantity of sample corresponding to approximately 10% of the
final drug concentration obtained in the solubility study was added to 300 mL of FaSSIF (ENRO:
25 mg, ENRO/Eudragit L100: 287.5 mg, ENRO/HPMCAS-LG: 967.5 mg and ENRO/HPMCAS-MG:
517.5 mg). One milliliter aliquots was taken at specific time points over the 2 h period of the study
and replaced with 1 mL of FaSSIF. Each sample was filtered with a 0.45 µm PTFE membrane filter
(VWR, USA) and diluted with a 2.9 g/L solution of phosphoric acid, previously adjusted to pH 2.3 with
triethylamine. The concentration of ENRO in each of the diluted samples was then measured by UV
spectrophotometry. The cumulative quantity of dissolved drug at each time point was calculated by
taking account of the 1 mL aliquots taken for analysis. Each study was carried out in triplicate.
2.2.12. UV Spectrophotometry
UV analysis was performed using a Shimadzu UV-1700 PharmaSpec UV-vis spectrophotometer
(Shimadzu Corp., Kyoto, Japan) using quartz cuvettes with a 1 cm optical path length. The reference
was a 2.9 g/L solution of phosphoric acid, previously adjusted to pH 2.3 with triethylamine. This buffer
was also used to produce a range of concentrations of pure ENRO, in order to construct a calibration
curve. The λmax of these solutions was found to be 277 nm; therefore, UV absorbance was measured at
this wavelength.
2.2.13. Bacterial Studies
For these studies, Staphylococcus aureus ATCC 25923, Escherichia coli ATCC 25922, Pseudomonas
aeruginosa ATCC 27853, and Klebsiella pneumoniae DSM 16609 were cultured on Columbia agar
supplemented with sheep blood. The inoculum was prepared as previously described [9,24]. The
density of the S. aureus suspension was adjusted so that it equaled that of the 1.1 McFarland standard,
and then further diluted 100-fold with BHI medium. The P. aeruginosa, E. coli, and K. pneumoniae
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suspensions, on the other hand, were adjusted to equal that of the 0.5 McFarland standard, and then
diluted 10-fold.
The minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations
(MBCs) of ENRO and the ASDs were determined using a broth microdilution method, as previously
described [9,24].
3. Results and Discussion
3.1. Production of Amorphous Solid Dispersions/Amorphous Polymeric Salts
Ball milling was first carried out on crystalline “as received” ENRO to determine whether it is
possible to amorphize the drug in this manner. However, following four hours of milling at room
temperature, a disordered, semi-crystalline solid was obtained (Figure 2a). This was also the case with
CIP [1]. The most intense peaks in the X-ray diffractogram of the unprocessed ENRO powder are
visible at 7.4, 9.8, 14.9, and 25.8 2θ degrees. These peaks are also present in the diffractogram of ball
milled ENRO; however, their intensity is reduced. Quench cooling ENRO, on the other hand, resulted
in an X-ray amorphous material (Figure 2a).
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Figure 2. Powder X-ray diffraction (PXRD) diffractograms of (a) enrofloxacin (ENRO) and
semi-crystalline solid dispersions, and (b) ENRO amorphous solid dispersions (ASDs).
In previous studies with CIP, X-ray amorphous solid dispersions were obtained when the drug
was ball milled with Eudragit L100, Eudragit L100-55, Carbopol, HPMCAS-LG, and HPMCAS-MG. All
of these polymers are acidic, and FTIR analysis confirmed the presence of an ionic bond between the
positively charged piperazine amino group of CIP and the carboxylate groups of the polymers in the
ASDs [9]. These acidic polymers also proved to be suitable co-formers for ENRO, with each resulting
in an X-ray amorphous formulation (Figure 2b). As was the case with CIP, a polymer concentration of
60% (w/w) was required to fully amorphize mixtures of CIP and HPMCAS, whereas 40% (w/w) was
adequate for Eudragit L100, Eudragit L100-55, and Carbopol. Although the product obtained with
40% (w/w) HPMCAS-LG was almost X-ray amorphous following 4 h of milling, very small peaks could
still be detected by PXRD at 9.8 and 25.8 2θ degrees, corresponding to the most prominent peaks of
anhydrous ENRO (Figure S1). A slightly more crystalline product was obtained with HPMCAS-MG
under the same conditions, which decreased in intensity following a further 2 h of milling but did not
disappear entirely. In contrast to CIP, which required a total of 6 h of milling and a reduced temperature
of 2–5 ◦C to form ASDs with 60% (w/w) HPMCAS [9], 4 h of milling at room temperature was adequate
for the corresponding ENRO ASDs (Figure S1). This indicates that the polymers may interact more
readily with ENRO than CIP possibly due to the weaker crystal lattice of ENRO, which would facilitate
its amorphization. These results show that the presence of an extra ethyl group in the structure of
ENRO does not appear to negatively affect its ability to interact with these acidic polymers. To enable
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closer comparison with the equivalent CIP ASDs, the ENRO/HPMCAS ASDs containing 60% (w/w)
polymer that were milled for 6 h were used for further studies.
In contrast to the acidic excipients, when CIP was milled with neutral polymers such as PVP and
PVA at a concentration of 40–60% (w/w), a semi-crystalline product was obtained [9]. This was also
the case with ENRO (Figure 2a). The fact that X-ray amorphous solid dispersions were only formed
when ENRO was milled with acidic polymers containing carboxylic acid groups suggests that the drug
is interacting with these substances via ionic bonds, as was the case with CIP. Likewise, in all of the
ENRO salts produced by Karanam et al. containing an acidic counterion, proton transfer from the acid
to the piperazine tertiary amine (N3) of the drug occurred, resulting in an ionic interaction between the
two moieties [2]. A similar reaction may take place between the N3 of ENRO and the polymers in
these ASDs.
3.2. Solid-State Fourier Transform Infrared Spectroscopy
The results of FTIR analysis of the ASDs, PMs, and starting materials are shown in Figure 3a–d.
A sharp peak is located at 1737 cm−1 in the spectrum of crystalline ENRO due to the carbonyl stretch of
its unionized carboxylic acid group. While the process of ball milling introduced some disorder to the
crystal lattice of ENRO, the FTIR spectrum of the ball milled drug was almost identical to the crystalline
ENRO starting material. The greater molecular disorder of quench cooled ENRO, on the other hand, is
evident in the broader and less intense peaks of its spectrum (Figure 3d). Slight peak shifts were also
seen with this sample, in particular, the carboxylic acid C=O stretch, which shifted to 1728 cm−1. This
can be attributed to changes in the drug’s intermolecular interactions upon amorphization, such as
hydrogen bonding [25]. Interestingly, the COOH carbonyl stretch of the drug also shifted to lower
wavenumbers in the spectrum of the crystalline ENRO saccharinate salt, in which the piperazine N3
amino group of the drug is positively charged [6]. This carbonyl peak underwent a similar shift with all
of the ASDs. Therefore, while the carboxylic acid of ENRO remains unionized in the ASDs, changes in
the hydrogen bonding of this group clearly occur upon amorphization. This shift may also be related
to changes in the ionization state of the drug.
The main differences between the spectra of ENRO and the ASDs may be seen in the 1650–1450 cm−1
region. In the case of crystalline ENRO, the carbonyl stretch of its ketone group appears as a sharp,
strongly absorbing peak at 1628 cm−1. The medium intensity shoulder at 1611 cm−1 may be assigned
to C=C stretching vibrations of the drug’s aromatic ring. While these peaks are not significantly
shifted in the spectra of the ASDs, differences in their relative absorbance were observed. In crystalline
ENRO, the absorbance of the ketone peak is approximately 1.8 times greater than that of the aromatic
peak. This ratio decreases to 1.5–1.7 for each of the ASDs. However, a similar decrease in the relative
absorbance of these peaks was also seen with quench cooled ENRO and is therefore likely due to
changes in the interactions of these groups upon amorphization.
The peaks at 1508 and 1469 cm−1 in the spectrum of ENRO may be attributed to C=C stretching of
the aromatic ring, and C–C stretching of the drug’s piperazine group, respectively [26]. The shape
of these peaks was altered notably in the ASDs, and the presence of multiple overlapping peaks
became evident. In order to separate the individual peaks in this region and to quantify their relative
absorbance, deconvolution of the spectra, with Gaussian peak fitting, was carried out. The resulting
spectra are shown in Figure S2. Deconvolution allowed the detection of a further peak at approximately
1453 cm−1 in the spectrum of ENRO, which may be tentatively assigned to the C–H bending vibrations
of the ethyl group. This peak is also present in the spectra of ball milled and quench cooled ENRO,
and all of the ASDs, along with an additional peak at approximately 1494 cm−1. Although a slight
broadening is visible at this wavenumber in the spectrum of crystalline ENRO, it is not as distinct as
with the other samples. Clear differences in the relative absorbance of these peaks may also be seen
between the pure drug and ASDs. For instance, in crystalline ENRO, the area of the peak at 1508 cm−1
is approximately two times smaller than the combined area of the peaks at 1469–1453 cm−1. While a
similar ratio was obtained with the equivalent peaks in ball milled ENRO, with the quench cooled
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form of the drug, it decreased to 1.9. With the ASDs, on the other hand, this ratio decreased further to
1.3–1.55. Similarly, in the spectra of crystalline and ball milled ENRO, the absorbance of the peak at
1469 cm−1 is clearly greater than that at 1453 cm−1. By contrast, in each of the ASDs, as well as quench
cooled ENRO, the maximum absorbance of these peaks did not differ greatly. Similar changes in this
region were seen in the spectra of the partially crystalline ENRO/PVA solid dispersion, whereas the
less disordered ENRO/PVP more closely resembled the crystalline ENRO starting material (Figure S3).
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Figure 3. FTIR spectra of ASDs and physical mixtures (PM) containing (a) Eudragit L100 and Eudragit
L100-55 40% (w/w) (b) Carbopol 40% (w/w), (c) hydroxypropyl methylcellulose acetate succinate grades
LG and MG (HPMCAS-LG and HPMCAS-MG) 60% (w/w), and (d) ball milled and quench cooled
ENRO. The areas of the spectra that undergo significant changes upon amorphization are highlighted
in violet.
As previously mentioned, the terminal tertiary amine of ENRO (N3) may be protonated in these
ASDs, forming ionic bonds with the carboxylate groups of the polymers. If this is the case, the
main differences in the FTIR spectra of the ASDs compared to the starting materials or PMs can be
attributed to the change in ionization state of the drug, and the presence of an additional +N–H bond.
Unfortunately, the +N–H stretch is difficult to assign with certainty, as it will produce a weak band in
the 3000–2600 cm−1 region that possibly overlaps with others, such as that of the C–H stretch of the
neighbouring aliphatic group [26]. Similarly, the +N–H bend of a tertiary amine salt generally appears
as a very weak band in the 1610–1500 cm−1 region [27] and therefore is likely to be obscured by more
intense peaks in the spectra of the ASDs. However, as described above, a number of differences in the
1450–1550 cm−1 region of the spectra of ENRO and the ASDs were observed. Therefore, it is possible
that the presence of the peak corresponding to the +N–H bend contributed to the variations in this area
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of the spectra. In addition, as the peaks in this region correspond to groups surrounding the terminal
amino group of ENRO, it is likely that they would be altered upon the protonation of N3.
The hypothesis that ENRO is protonated in these ASDs is supported by the FTIR analysis of
ENRO salts conducted by Karanam et al. [2]. In the spectra of each of the salts containing an acidic
counterion, a decrease in the absorbance of the peak around 1469 cm−1 relative to that at 1508 cm−1
can be seen, in common with the ENRO ASDs. Single crystal X-ray diffraction confirmed that the N3
of the drug was protonated in these salts and formed an ionic bond with the carboxylate groups of
the acids. Therefore, it is likely that ENRO is in the same cationic state in these ASDs and interacts
with the acidic groups of the polymers to form amorphous polymeric salts (APSs). The fact that the
spectrum of quench cooled ENRO is similar to that of the ASDs may be due to the partial conversion
of the drug to the zwitterion.
3.3. Thermal Analysis
The conventional DSC thermograms of ENRO and the ASDs are shown in Figure 4. The melting
point onset of crystalline ENRO, as well as the ball milled and quench cooled drug, was approximately
225 ◦C. Its lower melting point in comparison to CIP (approximately 272 ◦C) [1] can be explained by
the less extensive intermolecular bonds in ENRO. In contrast to the pure drug, the thermograms of the
ASDs were missing a clear melting point. Similarly, the ASDs did not show distinct crystallization
exotherms during DSC analysis, although the small, broad peaks visible at approximately 157 ◦C
and 148 ◦C in the thermograms of ENRO/HPMCAS-LG and ENRO/HPMCAS-MG, respectively, may
be due to some crystallization. The indistinct nature of the thermograms can be attributed to the
amorphous nature of these formulations and their stability upon heating [28]. By contrast, ball
milled and quench cooled ENRO had clear crystallization peaks at approximately 73 ◦C and 106 ◦C,
respectively, confirming their lower resistance to crystallization. The particularly low crystallization
temperature of ball milled ENRO is to be expected, as the residual crystallinity present in this sample
would enable crystal growth to occur more quickly upon heating.
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Figure 4. Differential scanning calorimetry (DSC) thermograms of (a) crystalline ENRO, (b) ball milled
ENRO, (c) quench cooled ENRO, (d) ENRO/HPMCAS-MG, (e) ENRO/HPMCAS-LG, (f) ENRO/Carbopol,
(g) ENRO/Eudragit L100-55, and (h) ENRO/Eudragit L100. The thermograms of the ASDs are those
obtained from the second heating cycle, following initial heating to 65 ◦C to allow for residual
water removal.
The Tg of quench cooled ENRO was detected at 58.9 ◦C, which is significantly lower than that
of CIP (86.7 ◦C). Again, this may be attributed to the weaker intermolecular interactions present in
ENRO. As a distinct Tg could not be found for all of the ENRO ASDs using conventional DSC; they
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were therefore analyzed by MTDSC. The resultant Tgs are listed in Table 1. In each case, a single Tg
was detected. This suggests that the drug is miscible with each of these polymers, and that they form a
single homogeneous phase [29]. Due to its low amorphous content and high crystallization rate, no Tg
could be determined for ball milled ENRO with either DSC technique.
The Gordon–Taylor (G–T) equation was used to calculate the expected Tgs of the ASDs, given
their weight percentage of drug and polymer. From Table 1, it can be seen that the experimental Tgs of
the ASDs containing Carbopol, Eudragit L100, and Eudragit L100-55 were substantially higher than
the theoretically derived values. Such large positive deviations from the predicted Tgs suggest that
strong interactions exist between the components and are particularly indicative of polymeric salt
formation [30]. By contrast, the experimental and G–T Tgs of the HPMCAS-containing ASDs differed
by only a few degrees. This suggests that these polymers are fully miscible with ENRO but do not
form strong interactions with the drug or that the heteromolecular drug–polymer interactions may be
of a similar strength to the homomolecular interactions present in the individual raw materials [31].
Similar results have been obtained with the equivalent CIP ASDs, whereby the experimental
Tgs of those containing Eudragit L100 and L100-55 deviated from the predicted values by a much
greater degree than those containing either grade of HPMCAS. The apparently weaker interactions
present in the latter ASDs were attributed to the lower proportion of carboxylic acid groups present in
HPMCAS compared to the other polymers [9]. This would explain why a polymer concentration of
60% (w/w) was required to produce X-ray amorphous solid dispersions with these polymers, whereas
a concentration of 40% (w/w) was sufficient with the others.
Table 1. Glass transition temperatures (Tg) of ENRO and ENRO ASDs.
Sample Experimental Tg (◦C) G-T Tg (◦C)
ENRO 58.9 N/A
ENRO/Eudragit L100 109.9 ± 1.6 82.5
ENRO/ Eudragit L100-55 103.2 ± 0.2 74.0
ENRO/Carbopol 155.6 ± 0.2 71.4
ENRO/HPMCAS-LG 86.8 ± 0.4 85.6
ENRO/HPMCAS-MG 83.3 ± 0.4 85.9
As previously mentioned, CIP exists as a zwitterion in the solid state, with a positively charged
piperazine amino group and negatively charged carboxylate group. However, it has been shown to
convert to the unionized form upon melting, due to intramolecular proton transfer. This was visualized
as a small endothermic peak in the DSC thermogram of the drug, just prior to the melting endotherm.
However, this low energy event was only visible when CIP was heated at 500 ◦C/min [1]. HSDSC
analysis was therefore carried out on crystalline ENRO in order to determine if it also undergoes
proton transfer at high temperatures, in this case from the unionized form to the zwitterion. However,
even when heated at the maximum heating rate of 500 ◦C/min, the drug did not show any evidence of
solid-state transformation (Figure S4). After heating ENRO to the endset of melting and allowing it to
cool slowly, PXRD and FTIR analysis confirmed that the drug remained in the unionized anhydrous
state; thus, the ethyl moiety attached to N3 prevented the proton transfer.
While crystalline ENRO is pale yellow, quench cooled ENRO is a more vibrant golden color,
and when heated to 250 ◦C, the drug becomes dark orange/rusty. CIP also turns from off-white to a
yellow color prior to melting; however, when heated past its melting point, it becomes brown due
to substantial degradation. From the TGA curves obtained with ENRO and the ASDs (Figure 5),
crystalline and ball milled ENRO do not appear to undergo substantial thermal degradation, decreasing
in mass by only 3.4% over the course of the TGA analysis. CIP, on the other hand, is much more prone
to thermal degradation, with a mass loss of 12.8% and 17.3% being obtained with the crystalline and
ball milled forms of the drug, respectively [1]. An initial mass loss was observed below 70 ◦C with all
of the amorphous formulations due to water evaporation. This is to be expected with ASDs, as the
hygroscopic nature of amorphous drugs and polymers results in the absorption of atmospheric water
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vapor. The amorphous samples also degraded to a greater degree than the pure drug, in particular, the
Carbopol ASD. Amorphous solids are typically more reactive than their crystalline counterparts, as
their higher molecular mobility can enable such degradation reactions to occur [32]. Alternatively, this
mass loss may simply be due to degradation of the polymers.Pharmaceutics 2019, 11, x FOR PEER REVIEW 12 of 20 
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Figure 5. TGA analysis of (a) crystalline ENRO, (b) ball milled (BM) ENRO, (c) ENRO/Eudragit L100,
(d) ENRO/Eudragit L100-55, (e) ENRO/Carbopol, (f) ENRO/HPMCAS-LG, and (g) ENRO/HPMCAS-MG.
3.4. Water Sorption Studies
The stability of the ASDs when exposed to various humidity levels was examined by DVS. At the
end of the sorption cycle, at 90% RH, ENRO absorbed only 0.13% (w/w) water. This increased to 2.9%
for the ball milled drug, due to the increase in disordered material (Figure 6a). CIP also absorbed low
levels of water during DVS analysis, increasing in mass by only 0.6% (w/w) [33]. PXRD analysis of the
drugs at the end of the sorption studies revealed that both ENRO remained in the same solid state, with
PXRD patterns matching those of the starting materials (Figure S5) [33]. In contrast to the crystalline
drug, the ENRO ASDs were far more hygroscopic, absorbing 16–19% of their mass in water. Very
similar levels of water uptake were observed with the CIP ASDs [9]. The higher hygroscopicity of the
amorphous formulations can be explained by the random orientation of their molecules. This leads to
a larger free volume and enables the penetration of water into the samples [34]. In addition, polymers
are often more hygroscopic than the amorphous form of a drug, which increases the tendency of an
ASD to take up moisture [35].
As can be seen in Figure 6b, the isotherms obtained with the ASDs containing Eudragit L100,
Eudragit L100-55 and Carbopol were very similar in shape, with significant hysteresis. Hysteresis is
commonly encountered with amorphous or porous solids, as water can absorb into the interior of the
material [36]. If water diffuses into the sample bulk more quickly than it can return to the surface, then,
at the same RH level, a greater amount of moisture will be present during desorption than sorption,
resulting in the appearance of hysteresis.
Unlike the other ASDs, the isotherms of both ENRO/HPMCAS ASDs were convex in shape with
a small amount of hysteresis, suggesting that water was mainly adsorbed to the outer surfaces of
these samples (Figure 6c). Therefore, the water uptake behavior of the ENRO ASDs differs depending
on the polymer used. This was further examined by fitting the sorption and desorption data to the
Young–Nelson equations. According to the Young–Nelson model, water can be taken up by a sample
in three different ways: adsorbed as a monomolecular layer, adsorbed as a multilayer, or absorbed into
the interior of the solid [22]. The parameters calculated using the Young–Nelson equations are listed in
Table S1, and the isotherms obtained using this approach are shown in Figure 7 and Figure S6. The
corresponding CIP ASDs were also examined for comparison (Figure S7).
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Figure 6. DVS isotherms of (a) crystalline and ball milled ENRO, (b) ENRO ASDs containing 40%
(w/w) Eudragit L100, Eudragit L100-55, and Carbopol, and (c) ENRO ASDs containing 60% (w/w)
HPMCAS-LG and HPMCAS-MG.
As predicted from the DVS isotherms, the major water uptake mechanism of the ENRO ASDs
containing Eudragit L100, Carbopol, and Eudragit L100-55 was water absorption (Figure 7a,b and
Figure S6a). The small degree of absorption that occurred with the ENRO/HPMCAS ASDs confirms
that they are somewhat porous, but less so than the other ASDs, as suggested by the minor hysteresis
in their DVS isotherms. Unlike the other samples, the majority of water taken up by ENRO/HPMCAS
ASDs was bound to their exterior surfaces as a multilayer. Multilayer formation begins at low RH
levels and appears to occur simultaneously with monolayer adsorption (Figure 7c and Figure S6b). By
contrast, the major water uptake mechanism for the CIP ASDs containing HPMCAS was absorption
(Figure S7). This suggests that the CIP/HPMCAS ASDs are more porous than the corresponding ENRO
ASDs, or the polymers may be capable of swelling to a greater degree in the former formulations.
As with the ENRO ASDs, water is primarily absorbed into the interior of the CIP ASDs containing
Eudragit L100, Eudragit L100-55, and Carbopol. However, the water distribution patterns obtained
with the ENRO and CIP ASDs containing Carbopol differed somewhat from the others. The monolayer
adsorption of these samples increased more gradually over the course of the study and was also more
extensive. This may be due to the presence of more hydrophilic groups on the surface of these ASDs,
which can interact with water molecules [23].
With both sets of ASDs, the highest value of E was obtained with those containing HPMCAS-LG,
followed by HPMCAS-MG (Table S1). However, this constant was more than 10 times larger for
the ENRO/HPMCAS samples than those containing CIP. This indicates that water molecules form
much stronger and extensive interactions with the surface of these samples [37] and explains why
water appears to be mainly adsorbed to the surface of these ASDs in a multilayer. The value of the
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regression coefficient, r, was ≥0.98 for all of the ASDs, showing that there was a good fit between the
experimental and estimated values of the different parameters (Table S1). Therefore, application of the
Young–Nelson model is a suitable approach for comparing the water uptake of these samples.Pharmaceutics 2019, 11, x FOR PEER REVIEW 14 of 20 
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The permeation of water molecules into the interior of an amorphous solid can increase its free
volume, resulting in a decrease in Tg [38]. Water sorption is also known to increase the molecular
mobility and thus crystallization rate of amorphous substances, and to decrease the crystallization
onset temperature [39]. However, despite the plasticizing effects of sorbed water, all five of the ENRO
ASDs remained X-ray amorphous following DVS analysis (Figure S5). This was also the case for the
corresponding CIP polymeric ASDs [9]. The high stability of these ASDs may be due to stabilizing
drug–polymer interactions, the presence of which was suggested by the results of FTIR and DSC
analysis. Polymers are also known to have anti-plasticizing effects and to reduce the molecular mobility
of amorphous formulations, while steric hindrance from polymer chains can prevent the nucleation
and crystal growth of drug molecules [8,40]. In contrast to the polymeric ASDs, amorphous CIP salts
containing succinic acid or amino acids as counterions were unstable in humid environments and
crystallized during DVS studies [33].
3.5. Solubility and Dissolution Studies
Due to issues with clumping and viscosity, solubility studies could not be carried out accurately on
the ASDs containing Eudragit L100-55 and Carbopol, and these samples were therefore excluded from
further studies. The superior solubility of the remaining ASDs in FaSSIF in comparison to crystalline
ENRO is clear from Figure 8a. With the pure drug, a peak in concentration was seen at 30–60 s, which
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then quickly fell to a constant level of approximately 0.7 mg/mL. A steep initial increase in drug
concentration was also seen with the ASDs containing HPMCAS-LG and HPMCAS-MG, which peaked
after 5 and 2 min, respectively. While this supersaturation then fell after 10–15 min, the concentration
was still significantly higher than that obtained with crystalline ENRO. This solubility enhancement
was sustained for the remainder of the study, with final concentrations of 12.2 mg/mL and 5.6 mg/mL
being obtained with ENRO/HPMCAS-LG and ENRO/HPMCAS-MG, respectively. In contrast to the
other samples, a more gradual increase in drug concentration was seen with ENRO/Eudragit L100,
followed by a plateau after 20 min. This sample was also less soluble than those containing HPMCAS,
reaching a concentration of 4.6 mg/mL after 2 h.
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The dissolution behavior observed with these ASDs is similar to that described by the “spring” and
“parachute” model [41]. In this model, ASDs are described as “springs”, as their high energy and lack
of a crystal lattice results in rapid drug dissolution and supersaturation. However, this supersaturated
state is thermodynamically unstable, and crystallization of a lower energy, less soluble form of the drug
soon follows. Fortunately, excipients such as polymers may be used to inhibit or delay the precipitation
of dissolved drug and thus act as “parachutes” [41]. Polymers can prevent nucleation and crystal
growth via interactions with the drug, steric hindrance, and increased viscosity [42]. Although the
concentration obtained with the ENRO/HPMCAS ASDs did decrease somewhat over the course of
the study, the polymers present in these ASDs most likely prevented extensive crystallization of the
drug in solution, enabling supersaturation to be maintained for at least 2 h. By avoiding the rapid
generation of supersaturation, less nucleation and crystallization would be expected to occur with the
ENRO/Eudragit L100 ASD. This was confirmed by PXRD analysis of the excess solid recovered at the
end of the solubility studies. In each case, enrofloxacin hexahydrate [2] was detected; however, with
ENRO/Eudragit L100, the sample was far less crystalline (Figure S8).
Similarly enhanced concentrations were obtained with the ENRO ASDs in dissolution studies
in comparison to crystalline ENRO. Following 2 h, the highest concentration was achieved
with ENRO/HPMCAS-LG, at 1.45 ± 0.03 mg/mL (44.8 ± 1.2% of ENRO released), followed by
ENRO/HPMCAS-MG (0.70 ± 0.01 mg/mL, 40.5 ± 0.6% of ENRO released) and ENRO/Eudragit
L100 (0.55 ± 0.02 mg/mL, 57.4 ± 1.8% of ENRO released). Crystalline ENRO, on the other hand,
only attained 0.09 ± 0.00 mg/mL (104.7 ± 4.5% of ENRO released) over the course of the study
(Figure 8b). Apart from concentration, the ASDs also differed in the shape of their dissolution profiles.
With ENRO/HPMCAS-LG, the drug concentration increased quite rapidly at the start of the study
and then remained fairly constant for the remainder. While a similar profile was obtained with
ENRO/HPMCAS-MG, the initial drug release was more gradual than with the LG grade of polymer.
As was the case in the solubility study, the final concentration obtained with ENRO/HPMCAS-MG
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was approximately half that of ENRO/HPMCAS-LG. However, ASDs containing different grades of
HPMCAS are known to demonstrate different rates and extents of drug release, due to differences in
their succinoyl and acetyl content [43]. This may affect the pH of the diffusion layer surrounding the
ASD particles, or the strength of drug–polymer interactions.
A steady, linear increase in drug concentration was observed with ENRO/Eudragit L100. As no
leveling off occurred during the study, it is possible that the drug concentration would continue to
rise during longer-term studies, similar to an extended release formulation. The gradual dissolution
of ENRO from this ASD may be due to strong drug–polymer interactions, which could delay the
dissociation and dissolution of the drug [44]. Such interactions would also explain the higher than
predicted Tg of this formulation and the absence of crystallization during DSC analysis, unlike the
ASDs containing HPMCAS. Alternatively, this polymer may be less soluble than HPMCAS, which
would reduce the diffusion of water into the ASD and, thus, its dissolution rate.
Visible differences in the behavior of the ENRO ASD powders were also evident during dissolution
studies. Both ENRO/Eudragit L100 and ENRO/HPMCAS-MG formed clumps when added to the
dissolution vessels. While these eventually dissolved in the case of ENRO/HPMCAS-MG, with
ENRO/Eudragit L100, they remained largely intact for the duration of the study. This would have
hindered the release of the drug and reduced the surface area exposed to the dissolution medium.
By contrast, no clumping was observed with ENRO/HPMCAS-LG, which enabled faster dissolution
and higher concentrations of ENRO to be achieved.
From the results of this study and that of a previous investigation involving CIP, it can be
concluded that ENRO is the more soluble of the two fluoroquinolones in FaSSIF. CIP was found to
have a solubility of only 0.14 mg/mL in this medium [9], which is five times lower than that of ENRO.
Higher drug concentrations were also obtained with the ENRO ASDs than the equivalent CIP ASDs.
Similarly, ENRO has been reported to be more soluble than CIP in pH 7.4 phosphate buffer [5]. As
previously mentioned, the greater solubility of ENRO may be explained by its weaker crystal lattice,
which would facilitate the release of drug molecules into solution.
3.6. Bacterial Studies
The minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs)
of ENRO and the ASDs are listed in Table 2. Values that differ significantly from those of ENRO are
shown in bold. In each case, the MBC should be greater than the MIC, as a larger quantity of drug is
required to bring about bacterial death rather than growth inhibition. If the ratio of MBC to MIC is ≤4,
this indicates that a drug is bactericidal [45], which was the case for ENRO and the ASDs in all species
of bacteria in this study. A MIC of ≤0.5 µg/mL may be considered as susceptible to ENRO, while
≥2 µg/mL indicates bacterial resistance, and 1 µg/mL is intermediate [46]. Therefore, from the results
of this study, it can be concluded that E. coli, S. aureus, and K. pneumoniae are susceptible to ENRO,
while P. aeruginosa is not. As was the case with CIP, E. coli was found to be the most susceptible of
these bacteria to ENRO, having a MIC of 0.004–0.0016 µg/mL. Quite low MIC levels were also obtained
in K. pneumoniae (0.032–0.125 µg/mL), followed by S. aureus (MIC 0.125–0.25 µg/mL). By contrast, much
higher MIC and MBC values of 4–8 µg/mL were obtained with P. aeruginosa. However, the outer
membrane of this bacteria is known to be far less permeable than that of E. coli, while fluoroquinolones
are also believed to be substrates for an active eﬄux system within P. aeruginosa [47]. In each case, the
MIC values obtained for ENRO in these four species agree well with those reported previously [46].
As can be seen from Table 2, the formulation of ENRO as an ASD did not significantly
affect its antibacterial activity in any species of bacteria, while the MIC and MBC obtained with
ENRO/HPMCAS-MG was significantly lower in E. coli and K. pneumoniae than in the pure drug. Similar
results were previously obtained with CIP ASDs, whereby the MIC and MBC of CIP/HPMCAS-MG was
significantly lower than crystalline CIP in all four of these species, while the MIC of CIP/HPMCAS-LG
was also significantly reduced in E. coli, and its MBC was lower in both E. coli and S. aureus. These
ASDs were also found to increase the passive transmembrane permeability of CIP [9]. Therefore, it is
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possible that the formulation of ENRO as an ASD with HPMCAS-MG also improved its permeability,
enabling more of the drug to be transported through the bacterial cell membranes via passive diffusion.
Table 2. Minimum inhibitory concentration and minimum bactericidal concentration of enrofloxacin
and ASDs in various bacteria a.
Sample S. aureus P. aeruginosa E. coli K. pneumoniae
Minimum Inhibitory Concentration (µg/mL)
ENRO 0.25 4 0.016 0.125
ENRO/Eudragit L100 0.125–0.25 4 0.008–0.016 0.063–0.125
ENRO/HPMCAS-LG 0.125–0.25 4–8 0.008–0.016 0.063–0.125
ENRO/HPMCAS-MG 0.125 4 0.004–0.008 0.032–0.063
Minimum Bactericidal Concentration (µg/mL)
ENRO 0.25 4 0.032 0.25
ENRO/Eudragit L100 0.25 8 0.016 0.125
ENRO/HPMCAS-LG 0.125 8 0.016 0.125
ENRO/HPMCAS-MG 0.125 4 0.008 0.063
a The values shown in bold differ significantly from those of pure crystalline ENRO.
4. Conclusions
In this study, ball milling was successfully used to produce several ASDs of ENRO. Despite its
extra ethyl group, ENRO behaved similarly to CIP in terms of polymer compatibility, with each drug
only forming X-ray amorphous ASDs with acidic polymers. The results of FTIR analysis indicate that
the terminal tertiary amine of ENRO is protonated in these ASDs and forms an ionic bond with the
carboxylate groups of the polymers. The high Tgs of the ASDs and their resistance to crystallization
during DSC analysis reinforces the suggestion that strong interactions exist between the components
and formation of amorphous polymeric salts. Although the ASDs were hygroscopic, they remained
X-ray amorphous during water sorption studies due to the stabilizing effects of the polymers. The ASDs
also generated significantly higher drug concentrations than crystalline ENRO during solubility and
dissolution testing, and these levels were sustained for the duration of the studies. As the prolongation
of supersaturation is believed to increase drug absorption, the in vivo absorption of these formulations
is likely to be superior to that of the pure drug. In addition, the antimicrobial activity of ENRO was not
decreased by ASD formation, while it was improved by ENRO/HPMCAS-MG in E. coli and S. aureus.
This study has therefore demonstrated that the formulation of ENRO as a polymeric ASD, or more
accurately, an APS, can improve a number of the drug’s biopharmaceutical properties, making this an
attractive formulation option.
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